|Target disease||Glaucoma / Ocular hypertension|
|Development stage||phase I / IIa trial in U.S.|
|License out to||in-house developed
（contractor : Allysta Pharmaceuticals, Inc.）
|Overview||This product is a multikinase inhibitor that inhibits various kinds of protein kinases, including leucine-rich repeat kinase (LRRK),and is suggested to stimulate the drainage of aqueous humor from the main outflow tract via the trabecular meshwork and Schlemm’s canal, thus lowering intraocular pressure. The long-term persistence of this potent intraocular pressure-lowering effect has been demonstrated in animal studies.
We made a presentation of the effect of treatment for exudative age-related macular degeneration (wet AMD) jointly with Mie University at ARVO (*) held in May 2015.
In September 2018, phase I / IIa clinical trial in U.S. was completed with good results. Currently, we are promoting licensing out activities.
※The Association for Research in Vision and Ophthalmology
|2016||Apr.||Initiated non-clinical studies|
|2018||Jan.||Completed non-clinical studies|
|Mar.||Initiated phase I / IIa trial in U.S.|
|Sep.||Completed phase I / IIa trial in U.S.|
Examination of expansion of the indications of H-1337
From 2017, we have started collaborative research for “H-1337” indication of pulmonary hypertension with Chiba University. “H-1337” has been shown to improve lung hemodynamics of pulmonary arterial pulmonary hypertension rat model “Su/Hx rat model” and has been shown that there is a possibility of suppressing cell proliferation in the pulmonary artery. From now on, we promote collaborative research and hope to be able to create new possibilities for H-1337.